Stable Istotope Labelled Dinutuximab Biosimilar – Anti-ganglioside GD2 mAb – Research Grade

Reference: PX-TA1323-SIL-1MG
Product nameStable Istotope Labelled Dinutuximab Biosimilar - Anti-ganglioside GD2 mAb - Research Grade
SourceCAS 1363687-32-4
SpeciesChimeric
Expression systemMammalian cells
Molecular weight145kDa
Purity>95%
BufferPBS buffer PH7.5
Delivery conditionBlue Ice
Delivery Time3-5 days if in stock; 5-8 weeks if production needed
Storage conditionstore at -80°C
BrandProteoGenix
Aliases /Synonyms14.18,MAb-14.18,MOAB Ch14.18
ReferencePX-TA1323-SIL
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG1-kappa
ClonalityMonoclonal Antibody
FormatLyophilized
LabellingArginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99%
Isotopic Enrichment99%
Stability1 year

General information on Anti-ganglioside GD2[Homo sapiens] (Dinutuximab) Monoclonal Antibody

Dinutuximab is ahuman/mouse chimeric monoclonal antibody of isotype IgG1 that targets GD2. GD2 is a disialoganglioside expressed on neuroectodermal tumors, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. By binding to GD2, dinutiximab induces apoptosis and inhibits the proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), to treat childrens with high-risk neuroblastoma.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Stable Istotope Labelled Dinutuximab Biosimilar – Anti-ganglioside GD2 mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Contact us

Send us a message from the form below